Patents by Inventor Joseph E. Blaney

Joseph E. Blaney has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES
    Publication number: 20180008693
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Application
    Filed: July 14, 2017
    Publication date: January 11, 2018
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Attenuated mutant dengue viruses comprising a mutation in the NS4B non-structural protein
    Patent number: 9707287
    Abstract: The invention features novel attenuated dengue virus mutants and compositions thereof. The invention further features an attenuated dengue virus comprising a proline to leucine change at amino acid position 2343 of non-structural protein 4B (NS4B), wherein the numbering is based upon the prototypic isolate DEN4 Dominica 1981 and the attenuated mutant DEN virus has at least one of the following properties: improved replication in Vero cells or restricted replication in mosquito cells.
    Type: Grant
    Filed: December 4, 2013
    Date of Patent: July 18, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Development of dengue virus vaccine components
    Patent number: 9090873
    Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3?untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5?direction as far as the 5?boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.
    Type: Grant
    Filed: December 3, 2012
    Date of Patent: July 28, 2015
    Assignee: The United States of America, as represented by the Secretary of the Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy, Ching-Juh Lai
  • DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES
    Publication number: 20150064214
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Application
    Filed: December 4, 2013
    Publication date: March 5, 2015
    Applicant: The USA, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • CONSTRUCTION OF WEST NILE VIRUS AND DENGUE VIRUS CHIMERAS FOR USE IN A LIVE VIRUS VACCINE TO PREVENT DISEASE CAUSED BY WEST NILE VIRUS
    Publication number: 20140294892
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • MULTIVALENT VACCINES FOR RABIES VIRUS AND FILOVIRUSES
    Publication number: 20140212434
    Abstract: The present invention provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a filovirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a filovirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present invention provides a recombinant rabies virus vector omprising a nucleotide sequence encoding at least one filovirus glycoprotein or an immunogenic fragment thereof, as well as pharmaceutical compostions comprising the vaccine vectors.
    Type: Application
    Filed: February 2, 2012
    Publication date: July 31, 2014
    Applicant: The United States of America, as represented by the Secretary,Department of Health & HumanServices
    Inventors: Joseph E. Blaney, Jason Paragas, Peter Jahrling, Reed Johnson, Matthias Schnell
  • Construction of West Nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by West Nile virus
    Patent number: 8778671
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines.
    Type: Grant
    Filed: June 18, 2004
    Date of Patent: July 15, 2014
    Assignees: The United States of America, as represented by the Secretary of the Department of Health & Human Services, The Walter Reed Army Institute of Research
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney, Jr.
  • Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3? untranslated region
    Patent number: 8632782
    Abstract: The invention features novel attenuated dengue virus mutants and compositions thereof.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: January 21, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Development of dengue virus vaccine components
    Patent number: 8337860
    Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.
    Type: Grant
    Filed: August 15, 2007
    Date of Patent: December 25, 2012
    Assignee: The United States of America, as represented by the Secretary of the Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy
  • DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES
    Publication number: 20120114694
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Application
    Filed: September 22, 2011
    Publication date: May 10, 2012
    Applicant: The Government of the USA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney
  • Recombinant attenuated dengue viruses comprising a deletion in the 3? untranslated region and additional attenuating mutations induced by chemical mutagenesis
    Patent number: 8039003
    Abstract: The invention provides compositions featuring an attenuated dengue virus mutant or an attenuated chimeric dengue virus mutant.
    Type: Grant
    Filed: March 2, 2009
    Date of Patent: October 18, 2011
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney
  • CHIMERIC SLE/DENGUE TYPE 4 ANTIGENIC VIRUSES
    Publication number: 20100316670
    Abstract: Embodiments described herein concern attenuated, St. Louis Encephalitis Virus/dengue virus type 4 antigenic chimeric viruses, which can be used to prepare immunogenic compositions, vaccines, and diagnostic reagents. Methods of making and using the foregoing are provided.
    Type: Application
    Filed: June 10, 2008
    Publication date: December 16, 2010
    Inventors: Joseph E. Blaney, Brian R. Murphy, Alexander G. Pletnev, Stephen S. Whitehead
  • DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTS
    Publication number: 20100104598
    Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.
    Type: Application
    Filed: August 15, 2007
    Publication date: April 29, 2010
    Applicant: The Government of the U.S.A., as represented by the Secretary, Dept. of Health
    Inventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy
  • DEVELOPMENT OF MUTATIONS USEFUL FOR ATTENUATING DENGUE VIRUSES AND CHIMERIC DENGUE VIRUSES
    Publication number: 20090263424
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Application
    Filed: March 2, 2009
    Publication date: October 22, 2009
    Applicant: Government of the United States of America, as represented by the Secretary, Department Health
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney
  • Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
    Patent number: RE45016
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: July 15, 2014
    Assignee: The United States of America, as represented by the Secretary of the Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Attenuated dengue virus comprising mutations in the NS3 gene
    Patent number: RE45053
    Abstract: A menu of mutations was developed that is useful in fine-tuning the attenuation and growth characteristics of dengue virus vaccines.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: July 29, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Recombinant attenuated dengue viruses comprising a deletion in the 3? untranslated region and additional attenuating mutations induced by chemical mutagenesis
    Patent number: RE45123
    Abstract: The invention provides compositions featuring an attenuated dengue virus mutant or an attenuated chimeric dengue virus mutant.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: September 9, 2014
    Assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Kathryn A. Hanley, Joseph E. Blaney, Ching-Juh Lai
  • Development of dengue virus vaccine components
    Patent number: RE46042
    Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.
    Type: Grant
    Filed: May 16, 2013
    Date of Patent: June 28, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health & Human Services
    Inventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy, Ching-Juh Lai
  • Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3?-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
    Patent number: RE46631
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: December 12, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph E. Blaney, Kathryn A. Hanley, Ching-Juh Lai
  • Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3?-UTR of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4
    Patent number: RE46641
    Abstract: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (?30) in the 3?-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.
    Type: Grant
    Filed: May 17, 2013
    Date of Patent: December 19, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Stephen S. Whitehead, Brian R. Murphy, Lewis Markoff, Barry Falgout, Joseph E. Blaney, Kathryn A. Hanley, Ching-Juh Lai